Trump announces voluntary pricing agreements with nine new drug makers

President Donald Trump hosted a drug pricing event on Monday, joined by executives from several pharmaceutical companies and senior health officials.

At the meeting he announced voluntary pricing deals with nine new companies, marking the first time the administration has extended such agreements beyond the original group of firms targeted in earlier letters.

The expansion suggests a broader, collaborative approach to drug pricing, though the specific terms of the agreements were not disclosed.